Zacks: Analysts Expect Denali Therapeutics Inc (NASDAQ:DNLI) to Post -$0.49 Earnings Per Share

Share on StockTwits

Equities analysts expect Denali Therapeutics Inc (NASDAQ:DNLI) to announce ($0.49) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Denali Therapeutics’ earnings. The lowest EPS estimate is ($0.67) and the highest is ($0.14). Denali Therapeutics posted earnings per share of $0.79 during the same quarter last year, which suggests a negative year over year growth rate of 162%. The company is scheduled to issue its next earnings results on Tuesday, March 10th.

On average, analysts expect that Denali Therapeutics will report full-year earnings of ($2.02) per share for the current fiscal year, with EPS estimates ranging from ($2.18) to ($1.65). For the next year, analysts anticipate that the firm will post earnings of ($2.37) per share, with EPS estimates ranging from ($3.09) to ($1.23). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Denali Therapeutics.

DNLI has been the subject of several research analyst reports. ValuEngine lowered Denali Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, January 28th. Zacks Investment Research raised Denali Therapeutics from a “hold” rating to a “buy” rating and set a $21.00 price target for the company in a research note on Monday, January 13th. Goldman Sachs Group raised Denali Therapeutics from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $20.00 to $37.00 in a research note on Sunday, January 26th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $28.00 price target on shares of Denali Therapeutics in a research note on Friday, December 20th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $28.86.

NASDAQ:DNLI opened at $25.42 on Friday. The firm has a market capitalization of $2.44 billion, a price-to-earnings ratio of -35.80 and a beta of 2.05. Denali Therapeutics has a 52-week low of $14.24 and a 52-week high of $30.41. The stock has a fifty day moving average of $21.72 and a 200 day moving average of $18.50. The company has a debt-to-equity ratio of 0.16, a quick ratio of 10.59 and a current ratio of 10.59.

In related news, CEO Ryan J. Watts sold 42,185 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $18.02, for a total value of $760,173.70. Following the transaction, the chief executive officer now directly owns 12,505 shares of the company’s stock, valued at approximately $225,340.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Carole Ho sold 3,464 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $20.01, for a total value of $69,314.64. The disclosure for this sale can be found here. In the last three months, insiders sold 93,054 shares of company stock valued at $1,695,673. 21.20% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in DNLI. Tower Research Capital LLC TRC lifted its position in Denali Therapeutics by 1,721.7% in the 3rd quarter. Tower Research Capital LLC TRC now owns 2,095 shares of the company’s stock valued at $32,000 after acquiring an additional 1,980 shares in the last quarter. Aigen Investment Management LP bought a new position in Denali Therapeutics in the 4th quarter valued at approximately $52,000. NumerixS Investment Technologies Inc lifted its position in Denali Therapeutics by 260.6% in the 4th quarter. NumerixS Investment Technologies Inc now owns 3,606 shares of the company’s stock valued at $63,000 after acquiring an additional 2,606 shares in the last quarter. Quantbot Technologies LP bought a new position in Denali Therapeutics in the 4th quarter valued at approximately $77,000. Finally, Patriot Financial Group Insurance Agency LLC lifted its position in Denali Therapeutics by 390.0% in the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 4,900 shares of the company’s stock valued at $85,000 after acquiring an additional 3,900 shares in the last quarter. 73.64% of the stock is currently owned by institutional investors and hedge funds.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

Read More: Quiet Period

Get a free copy of the Zacks research report on Denali Therapeutics (DNLI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Skandinaviska Enskilda Banken  Downgraded by ValuEngine
Skandinaviska Enskilda Banken Downgraded by ValuEngine
Boingo Wireless  Cut to Hold at Zacks Investment Research
Boingo Wireless Cut to Hold at Zacks Investment Research
Zacks: Global Indemnity Ltd  Given Average Rating of “Hold” by Analysts
Zacks: Global Indemnity Ltd Given Average Rating of “Hold” by Analysts
RMR Group  – Analysts’ Weekly Ratings Updates
RMR Group – Analysts’ Weekly Ratings Updates
Perrigo  Stock Price Down 14.6% After Earnings Miss
Perrigo Stock Price Down 14.6% After Earnings Miss
WD-40  Raised to Hold at Zacks Investment Research
WD-40 Raised to Hold at Zacks Investment Research


 
© 2006-2020 Zolmax.